Home > Gastroenterology > DDW 2024 > STARS: Apraglutide shows efficacy in patients with SBS-IF

STARS: Apraglutide shows efficacy in patients with SBS-IF

Presented by
Dr Francisca Joly, Hopital Beaujon, France
Conference
DDW 2024
Trial
Phase 3, STARS
Apraglutide, a long-acting glucagon-like peptide-2 (GLP-2) analogue, significantly reduced parenteral support (PS) volume in patients with short bowel syndrome with intestinal failure (SBS-IF). Conducted across 73 centres in 18 countries, the trial confirmed the efficacy and safety of apraglutide in this population.

The phase 3, double-blind, placebo-controlled trial (NCT04627025) included 164 adults with SBS-IF, who were randomised 2:1 to receive either once-weekly subcutaneous apraglutide or placebo. Dr Francisca Joly (Hopital Beaujon, France) presented the findings [1].

Participants were stratified by intestinal anatomy (stoma or colon-in-continuity [CIC]) and received either 2.5 mg or 5 mg of apraglutide based on their weight. The primary endpoint was the relative change in weekly PS volume at week 24. Secondary endpoints included additional days off PS at weeks 24 and 48 and the total enteral autonomy at week 48.

The primary endpoint was met, with apraglutide-treated participants showing a significantly larger reduction in weekly PS volume at week 24 compared with placebo (-25.5% vs -12.5%; P=0.001), with the apraglutide treatment effect observed from week 8. In the stoma subgroup, the reduction was more pronounced (-25.6% vs -7.8%; P<0.001). Although the CIC subgroup showed a numerical benefit, it did not reach statistical significance (-25.2% vs -17.6%; P=0.179). A significant proportion of participants receiving apraglutide achieved an additional day off PS per week at week 24 (43% vs 27.5%; P=0.040).

Total enteral autonomy was reached in 6.4% of participants receiving apraglutide compared with 0% in the placebo group (P=0.006) at week 24. By week 48, it was reached in 12.5% in the apraglutide group compared with 7.4% in the placebo group (P=0.387). Apraglutide was well tolerated, with a low discontinuation rate due to adverse events (3.6% vs 1.9%).

“Apraglutide is the first once-weekly GLP-2 analogue to show significant efficacy in reducing PS volume in a phase 3 trial for participants with SBS-IF. The trial confirmed that apraglutide significantly reduces weekly PS volume and increases days off PS with a favourable safety profile,” Dr Joly summarised.

  1. Joly F, et al. Efficacy and safety of apraglutide once-weekly in patients with short bowel syndrome and intestinal failure (SBS-IF): results from the STARS study - a global phase 3 double-blind, randomized, placebo-controlled trial. 1057c, DDW 2024, 18–21 May, Washington, DC, USA.

Medical writing support was provided by Federica Angius.

Copyright ©2024 Medicom Medical Publishers



Posted on